



*Developing Novel Therapies
in Women's Health*



Breakthrough Solutions to Major Reproductive Disorders

Unique opportunity to develop two transformational products for tens of millions of women



- **First-in-class medicated vaginal ring for uterine fibroids and endometriosis**
- **Could generate >\$1B/year in each indication**



- **First-in-class single non-hormonal therapy for painful and heavy menstrual periods**
- **Projected Rx/OTC sales – up to \$0.5B/year (US only)**

Arkady Rubin, PhD

Chief Scientific Officer and Acting CEO

+1 347-385-0878

arubin@arstatinc.com

www.arstatinc.com

Devastating Conditions



At Least 40 Million US Women* Impacted

- 10% with **endometriosis**
- 25% with symptomatic **uterine fibroids**
- 30% with abnormally **heavy menstrual periods**
- 55% need medications for **menstrual pain**

PREMRING™ for Uterine Fibroids and Endometriosis

- Ultra-low doses of a specific well-studied SPRM** are delivered by a novel route, directly to affected tissue for strong and fast therapeutic action.
- Unlike most of hormonal therapies, Premring will NOT be associated with severe menopausal symptoms

ENHANTA™ for Painful and Heavy Menstrual Periods

- Enhanta is an oral drug formulation with an NSAID*** and a low dose of an antifibrinolytic agent (tranexamic acid)
- Innovatively combines two first-line therapies in a safest and most efficacious way

Multiple Continuation Patent Applications Planned

- Novel, products that were never considered or tested
- Early success in Germany – 3 issued patents
- 3 patents under review in the US, 2 more will be filed in 2017
- At least 6 continuation applications planned (US and ex-US)
- Developed by Arkady Rubin, PhD (Chief Scientific Officer)
 - Co-inventor of Ortho Tri-Cyclen Lo® - by far the best-selling US oral contraceptive (≈\$503M, 2015)
 - A holder of a U.S. patent (No. 9,675,622) for the first oral contraceptive designed for obese and overweight women

Keys to Success

- **Proven concept:** Robust scientific and clinical data
- **Proven feasibility:** Premring and Enhanta will be manufactured using existing technologies and prototypes
- **Known approvability criteria:** Rapid path to 505(b)(2) NDA
- **Straightforward R&D:** Early exit after completion of two clinical efficacy (dose-ranging, Phase 2b) studies.



for 15 million US women

Breakthrough Solutions



for >25 million US women

Solid Proprietary Position

Exit in 2.5-3 years

At least \$200M; most likely close to \$310M (upfront only)


*Prevalence among women aged 15-49 years **SPRM = Selective Progesterone Receptor Modulator

***NSAID = Nonsteroidal anti-inflammatory drug

Financing Sought
\$1,000,000 USD (Seed)

Offering up to 20% stake in the company

Projected 3-Year ROI



Contact Information
Arkady Rubin, PhD

Phone: +1 347-385-0878
Email: arubin@arstatinc.com
Website: www.arstatinc.com

Use of Funds

To support 9 months of operations. **Major milestones:**

- **Enhanta:** the pill is ready, pre-IND meeting, FDA endorsed program, IND is opened, marketing research completed
- **Premring:** the ring is developed, pre-IND meeting, uterine fibroids study endorsed, commercial assessment completed

Funding Details

- Exploring different funding options, including convertible debt
- Projected timing and amounts of future funding rounds will be disclosed to interested parties
- We will discuss ways to minimize dilution as much as possible

Impressive Fair Market Value at Exit

Biostrategy Analytics was engaged to determine a market value of Premring™ and Enhanta™ at exit (after Phase 2b studies)

Exit Valuation Scenarios	Premring (Fibroids)	Enhanta	Both
“Worst” Case	\$203M	\$87M	\$290M
“Realistic” Case	\$429M	\$189M	\$618M

80% probability that the value at exit will be **> \$300M**

50% probability that the value at exit will be **> \$600M**

Leadership and Advisory Team (Partial List)

Arkady Rubin, PhD, Chief Scientific Officer & Acting CEO - 25 years of industry experience, mostly in women’s health. Dr. Rubin has designed and executed tens of clinical trials, and provided major contribution to several successful NDAs.

Agis Kydonieus, PhD, Drug Development Advisor - President, Samos Pharmaceuticals (Consulting/ Drug Delivery/ Biomaterials Development/Uterine Fibroids and Endometriosis). Co-founder of the Controlled Release Society, holder of 55 U.S. patents.

Brian Cairns, BS, MBA, Business Development Advisor - 20+ years in Brand Management at major Pharmaceutical companies

Specialty Pharma Advisor (Women’s Health) - OB/GYN MD, CEO of a startup in women’s health. In the past - a senior executive in Big Pharma responsible for multiple successful R&D programs.

M&B IP Analysts, LLC - Ranked as one of the top patent firms